Stockreport

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update [Yahoo! Finance]

Intensity Therapeutics, Inc.  (INTS) 
PDF IT-01 Study manuscript of INT230-6 used alone in 64 refractory metastatic cancer patients published in the Lancet's journal eBioMedicine, including data for disease con [Read more]